Healthcare
Proteome Sciences plc(PMSNF)
Live Price
Offline$0.02
+0.00% today
1Y Change
-50.00%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- โ
- Revenue Growth
- -23.2%
- EPS Growth
- +9.6%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Proteome Sciences plc (PMSNF) is a Healthcare stock with listed on OTC. The stock last traded around $0.02 and down 50.0% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of -23.2%, EPS growth of +9.6%, a dividend yield of 0.0%. What stands out right now is revenue -23.2%, EPS +9.6%, free cash flow +86.4% with operating margin -71.0% and ROIC -34.3%. Valuation is more restrained than many high-expectation growth names at price/sales 1.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PMSNF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-23.2% vs +7.6% peer median
Operating Margin
Below sector median
-71.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 8, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -23.2% and EPS is at +9.6%, with operating margin around -71.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 8, 2026 | โ | +0.0% | +0.0% | +0.0% |
2025 Sep 15, 2025 | โ | +0.0% | +0.0% | +0.0% |
2025 Apr 10, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PMSNF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PMSNF Max Drawdown
-80.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PMSNF and SPY.
Company Overview
Proteome Sciences plc
Other OTC
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the important factor. It also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers. In addition, the company offers bioinformatics tools, including Proteome Discoverer for peptide sequence and TMT quantitation; SQuaT,CalDIT, and DIANA for normalized quantitative values and functional annotation at peptide and protein level; FeaST for visualization of data quality, class identifier model, and biomarker candidate lists; and FAT for identification of biological processes and cellular components showing variance. It primarily serves pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.
- Leadership
- Christopher Donovan James Pearce
- IPO Date
- Feb 22, 2010
- Employees
- 36
- Street Address
- Coveham House
- Mailing
- Cobham, KT11 3EP
- Region
- Cobham, GB
- Reporting Currency
- USD
- Investor Line
- 44 20 7043 2116
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.3
- Price/Book
- โ
Growth
- Revenue
- -23.2%
- EPS
- +9.6%
- Free Cash Flow
- +86.4%
Profitability
- Gross Margin
- -26.8%
- Operating Margin
- -71.0%
- Net Margin
- -81.5%
- ROE
- 33.8%
- ROIC
- -34.3%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.13
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.